AI Summary & Key Takeaways
AI InsightThese recurrences are closely related to survival.
📌 3 Key Takeaways
Abstract
Objective: We aimed to investigate the clinicopathological features and recurrence patterns of patients who were diagnosed with stage 2 high-grade serous ovarian cancer and received adjuvant chemotherapy after surgery. Material and Methods: 49 patients treated in our clinic between 1993-2021, who underwent total abdominal hysterectomy + bilateral salpingo-oophorectomy + pelvic-paraaortic lymph node dissection +/- omentectomy for high-grade serous ovarian cancer, received adjuvant chemotherapy, who were stage 2 according to the FIGO 2014 staging system was included in the study. Results: When the stage distribution of the patients was evaluated, stage IIA was detected 27 patients (55.1%), and IIB was detected 22 patients (44.9%). Recurrence developed in 16 (28.6%) of 49 patients (27 patients had stage IIA, 22 patients had IIB) Considering the recurrence areas of the patients with recurrence, only pelvic 3 (6,1%), only the abdomen 12 (24,5%), while abdominal + pelvic recurrence developed in 1 (2%) patient. While chemotherapy was given to 7 patients who developed relapse, secondary cytoreduction was applied to 1 patient. Chemotherapy was given to 8 patients in addition to secondary cytoreduction. Conclusion: In our clinic, 1170 patients were operated for serous ovarian cancer, and only 49 (4.18%) of them were high grade, stage 2 cancer according to the FIGO 2014 staging system. The recurrence rate in the patients included in our study was 28.6%. 7 patients who developed relapse were stage 2A (43.75%), and 9 patients were stage 2B (56.25%). The recurrence of the disease was seen in the abdomen at a rate of 75%. The recurrence rate in stage 2 patients is considerably high. These recurrences are closely related to survival.
Özet
Amaç: Evre 2 yüksek-grade seröz over kanseri tanısı alan ve cerrahi sonrasında adjuvant kemoterapi alan hastaların klinikopatolojik özellikleri ve nüks paternlerinin araştırılması amaçlanmıştır. Gereç ve Yöntem: Kliniğimizde 1993-2021 yılları arasında tedavi görmüş, yüksek-grade seröz over kanseri nedeniyle total abdominal histerektomi + bilateral salpingooferektomi + pelvik-paraaortik lenf nodu diseksiyonu +/- omentektomi yapılan, adjuvan kemoterapi alan, FIGO 2014 evreleme sistemine göre evre 2 olan, 49 hasta çalışmaya dahil edilmiştir. Bulgular: Hastaların evre dağılımı değerlendirildiğinde, evre IIA olan 27 hasta (%55,1), IIB olan 22 hasta (%44,9) idi. 49 hastanın 16’sında (%28,6) rekürrens gelişti. Rekürrens gelişen hastalarda nüks gelişen bölgelere bakıldığında sadece pelvik 3 (%6,1), sadece abdomen 12 (%24,5) iken abdominal + pelvik nüks 1 (%2) hastada gelişti. Nüks gelişen 7 hastaya kemoterapi verilirken, 1 hastaya sekonder sitoredüksiyon uygulandı. 8 hastaya ise sekonder sitoredüksiyona ek olarak kemoterapi verildi. Sonuç: Kliniğimizde 1170 hasta seröz over kanseri nedeniyle opere edilmiş olup bunların sadece 49 (% 4,18) tanesi yüksek gradeli, FIGO 2014 evreleme sistemine göre evre 2 kanserdir. Çalışmamıza dahil olan hastalarda nüks oranı %28,6’ dır. Nüks gelişen 7 hasta evre 2A (%43,75), 9 hasta evre 2B (%56,25) idi. Hastalığın nüksü %75 oranında batında görülmüştür. Evre 2 hastalarda nüks oranı azımsanamayacak derecede yüksektir. Bu nüksler sağkalımı yakından ilgilendirmektedir.